Eli Lilly reaffirms its commitment to invest in Mexico

MEXICO - Ilya Yuffa, executive vice president and president of Eli Lilly and Company, reaffirmed the pharmaceutical firm's commitment to maintain its investment in clinical research in Mexico.

The executive emphasized that the growth of Eli Lilly's product portfolio and the progress in research and development open the possibility of significantly increasing its investments in Mexico and Latin America.

“Our ambitious product portfolio and our research give us the opportunity to continue to invest in the region. There is great potential to increase our investments in the future,” he added.

During the Forbes Health Summit: The Power of Innovation, presented by Eli Lilly, the pharmaceutical company announced that the investment will be directed to clinical development projects, with the aim of improving global health.

Eli Lilly has quadrupled the amount of investment in clinical research from 2019 to 2024, from US$17 million to US$103 million. This investment will continue to grow in the coming years.

In addition, Ilya Yuffa, executive vice president and president of Eli Lilly and Company, highlighted the company's commitment to innovation and research in the healthcare sector.

“We have been providing solutions for people with diabetes for more than 100 years, since we produced the first insulin. Today, we remain dedicated to pursuing innovative science that pushes the boundaries of what is possible to discover the medicines of tomorrow,” he said.

Yuffa also mentioned that the company is working to accelerate the development of new drugs, reducing research time from 11 to 6 years. This effort is focused on diseases such as diabetes, obesity and cardiovascular diseases, which have gained great relevance in Latin America.